期刊文献+

Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma

Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma
下载PDF
导出
摘要 BACKGROUND: Hepatocellular carcinoma (HCC) which is always refractory to most chemotherapeutic agents may result in poor survival of patients with advanced HCC. Oncolytic adenovirus is a new form for cancer gene therapy via its ability to replicate and kill tumor cells in a tumor-specific manner. In order to eradicate tumors effectively, the combination of chemotherapeutic agents and oncolytic adenovirus has been considered. This study aimed to systematically analyze the possibility of synergistic cytotoxicity of oncolytic adenoviruses in combination with chemotherapeutic agents. METHODS: Several types of human HCC cell lines were used to determine the specificity and cytotoxicity of oncolytic adenovirus Ad5-HC and Ad5-AFP (IRES) by measuring cell viability in vitro and antitumor efficiency in vivo. The cytotoxicity of Ad5-HC and Ad5-AFP (IRES) combined with chemotherapeutic agents were also assessed by the methyl thiazolyl tetrazolium assay. RESULTS: Both Ad5-HC and Ad5-AFP (IRES) were significantly cytotoxic to HCC cells with great specificity in vitro and in vivo. The combination of oncolytic adenovirus with 5-FU, doxorubicin, and paclitaxel was synergistically effective for the killing of HCC cells. CONCLUSIONS: These data suggest that oncolytic adenovirus sensitize tumors to chemotherapy and the combination therapy of chemotherapeutic agents and oncolytic adenovirus has an enhanced antitumor effect on HCC cells. (Hepatobiliary Pancreat Dis Int 2009; 8: 282-287) BACKGROUND: Hepatocellular carcinoma (HCC) which is always refractory to most chemotherapeutic agents may result in poor survival of patients with advanced HCC. Oncolytic adenovirus is a new form for cancer gene therapy via its ability to replicate and kill tumor cells in a tumor-specific manner. In order to eradicate tumors effectively, the combination of chemotherapeutic agents and oncolytic adenovirus has been considered. This study aimed to systematically analyze the possibility of synergistic cytotoxicity of oncolytic adenoviruses in combination with chemotherapeutic agents. METHODS: Several types of human HCC cell lines were used to determine the specificity and cytotoxicity of oncolytic adenovirus Ad5-HC and Ad5-AFP (IRES) by measuring cell viability in vitro and antitumor efficiency in vivo. The cytotoxicity of Ad5-HC and Ad5-AFP (IRES) combined with chemotherapeutic agents were also assessed by the methyl thiazolyl tetrazolium assay. RESULTS: Both Ad5-HC and Ad5-AFP (IRES) were significantly cytotoxic to HCC cells with great specificity in vitro and in vivo. The combination of oncolytic adenovirus with 5-FU, doxorubicin, and paclitaxel was synergistically effective for the killing of HCC cells. CONCLUSIONS: These data suggest that oncolytic adenovirus sensitize tumors to chemotherapy and the combination therapy of chemotherapeutic agents and oncolytic adenovirus has an enhanced antitumor effect on HCC cells. (Hepatobiliary Pancreat Dis Int 2009; 8: 282-287)
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2009年第3期282-287,共6页 国际肝胆胰疾病杂志(英文版)
基金 supported by grants from the National Natural Science Foundation of China(30572155) Zhejiang Provincial Natural Science Foundation of China(R206060).
关键词 hepatocellular carcinoma drug resistance oncolytic adenovirus CHEMOTHERAPY hepatocellular carcinoma drug resistance oncolytic adenovirus chemotherapy
  • 相关文献

参考文献29

  • 1Li JL,Liu HL,Zhang XR,Xu JP,Hu WK,Liang M,et al.A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Therapy . 2009
  • 2Montero J,Morales A,Llacuna L,Lluis JM,Terrones O,Basanez G,et al.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Research . 2008
  • 3Kumar S,Gao L,Yeagy B,Reid T.Virus combinations and chemotherapy for the treatment of human cancers. Current Opinion in Molecular Therapeutics . 2008
  • 4LaCasse EC;Baird S;Komeluk RG.The inhibitors of apoptosis (IAPs) and their emerging role in cancer,1998(17).
  • 5Bischoff JR,Kirn DH,Williams A,et al.An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science . 1996
  • 6Kurihara T,Brough D E,Kovesdi I,et al.Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. The Journal of Clinical Investigation . 2000
  • 7Park YM,Choi JY,Byun BH,et al.Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Experimental and Molecular Medicine . 1998
  • 8Kawakami Y,Kitamoto M,Nakanishi T,et al.Immunohistochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncegene . 2000
  • 9Szakacs G,Paterson JK,Ludwig JA,et al.Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery . 2006
  • 10Nies AT,Konig J,Pfannschmidt M,et al.Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. International Journal of Cancer . 2001

二级参考文献5

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部